Pricing Log in Create free account

Lakewood-Amedex Biotherapeutics Inc. (LABT) vs Valion Bio, Inc. (VBIO)

Lakewood-Amedex Biotherapeutics Inc. and Valion Bio, Inc. are both Biotechnology companies. Lakewood-Amedex Biotherapeutics Inc. is the larger, with a market value of $1.3M against $1.1M — 1.2× the size. Across the 10 metrics below, Lakewood-Amedex Biotherapeutics Inc. leads on 7 and Valion Bio, Inc. on 3.

Valuation

Metric LABT VBIO Biotechnology median
P/E n/m n/m 10.60
P/S n/m 0.14 9.40
P/B 0.12 0.02 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.71 n/m 0.66
EV/Sales n/m 11.09 9.02
Earnings yield (2,135.14%) (40,026.00%) (32.88%)
Free cash flow yield (934.12%) (22,510.36%) (23.13%)

Profitability

Metric LABT VBIO Biotechnology median
Gross margin — (58.09%) 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% (489.30%) (51.96%)
Return on assets (302.50%) (104.96%) (46.06%)
Return on invested capital 0.00% (61.01%) 0.00%

Growth

Metric LABT VBIO Biotechnology median
Revenue growth (TTM) — (49.63%) 6.76%
EPS growth (last fiscal year) 15.32% 60.16% 29.88%
Revenue growth, 5-year CAGR — 13.18% 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric LABT VBIO Biotechnology median
Debt to equity 0.00 0.62 0.00
Current ratio 7.70 1.11 4.97
Net debt to EBITDA 0.06 0.79 1.01

Dividend

Metric LABT VBIO Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric LABT VBIO Biotechnology median
Market cap 1.27m 1.08m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack